What is the current stock price of Revive Therapeutics Ltd. (RVVTF)?

As of the latest market data, Revive Therapeutics Ltd. (RVVTF) is trading at $0.02. The stock has seen a gain of 2.17% today.

Does Revive Therapeutics Ltd. (RVVTF) pay a dividend?

Based on current data, Revive Therapeutics Ltd. does not have a confirmed active dividend policy.

What is the market cap of Revive Therapeutics Ltd.?

The current market capitalization of Revive Therapeutics Ltd. (RVVTF) is approximately unavailable.

RVVTF

Revive Therapeutics Ltd.·Healthcare

0.02

2.167%(+0.00)

Close Price

0.02

8.238%(−0.00)

After Hours

Last Updated: — ET

52W L: $0.0152W H: $0.06

RVVTF NEWS

accessnewswire.com

May 20

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpiling TORONTO, ON / ACCESS Newswire / May 20, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, today announced its strategic expansion plan for bucillamine across infectious disease, defence and biothreat-related applications.

accessnewswire.com

Mar 11

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, is pleased to announce two important intellectual property milestones for bucillamine: (i) the filing of the U.S. and Canadian national phase patent applications under PCT/CA2024/000008 for "Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent," and (ii) the grant of Canadian Patent No.

Company Profile

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

2015-12-02

Beta

-1.83

Websitewww.revivethera.com↗